Clinical Analysis Of Gemcitabine Combined Regimen Of79Cases Of Metastatic Breast Cancer

Objective:A retrospective analysis of patients with metastatic breast cancer(MBC)of two chemical treatments, the two methods of recent clinical efficacy and toxicity were compared in order to provide new ideas and methods for the treatment of advanced metastatic breast cancer. Methods:A retrospective analysis of the Second Affiliated Hospital of Xinjiang Medical University, Department of Oncology, Cancer Hospital from January2011to June2013for anthracycline and(or) after taxane treatment of79cases of short-term progress in women of advanced metastatic breast contains the clinical data of patients with cancer, according to the selected treatment programs divided into two groups, one group of gemcitabine plus cisplatin, a group of gemcitabine plus capecitabine. Result:79patients to receive gemcitabine plus cisplatin(GP program)38cases of chemotherapy, gemcitabine plus capecitabine(GX program) chemotherapy in41cases.79cases of patients with advanced metastatic breast cancer were applied GX, GP two chemotherapy regimens its efficiency of47.3%and39%, respectively, disease control rate was81.5%and73.1%, respectively. The results showed that GP group of diseases efficiency and disease control rate was slightly better than GX group, but after the χ2test, the two groups have efficiency and disease control rate was no significant difference(P>0.05). There were no treatment side effects mainly caused death cases caused by chemotherapy is:The incidence of bone marrow suppression GP group81.6%(31/38) respectively, GX group68.3%(28/41); gastrointestinal reactions (nausea and vomiting) incidence of34.2%for the GP group (13/38) respectively, GX group14.6%(6/41). In addition, some patients had alopecia, rash, hand-foot syndrome, anemia, fatigue, mouth ulcers and mild damage to liver and kidney function, by giving symptomatic supportive treatment can alleviate, chemotherapy does not affect normal. After statistical analysis, GP Group gastrointestinal reactions is higher than the GX group, P<0.05, and hand-foot syndrome is lower than the GP group GX group, P<0.05, other toxicities were no significant statistical difference.Conclusion:79cases of patients with advanced metastatic breast cancer observed in this experiment, after gemcitabine plus chemotherapy recent efficacy, clinical benefit is good, mild side effects after symptomatic treatment can be tolerated, safe, Program can be considered to become a multi-line advanced metastatic breast cancer chemotherapy.